Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Harhausen, Denise ^a   Khojasteh, Uldus ^a   Stahel, Philip F ^b   Morgan, B Paul ^c   Nietfeld, Wilfried ^d   Dirnagl, Ulrich ^a   Trendelenburg, George ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD59 ANTIGEN; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CD59A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN SIZE; CELL DEATH; CONTROLLED STUDY; FEMALE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; REPERFUSION INJURY; ANIMAL; BRAIN INFARCTION; C57BL MOUSE; CEREBRAL ARTERY DISEASE; DISEASE MODEL; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; NEUROLOGIC EXAMINATION; PATHOLOGY; SEX DIFFERENCE; TIME;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD59; BRAIN INFARCTION; DISEASE MODELS, ANIMAL; FEMALE; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROLOGIC EXAMINATION; SEX FACTORS; TIME FACTORS;

EID: 77950413671     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-15     Document Type: Article

References (61)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397. 10.1016/S0166-2236(99)01401-0, 10441299.
2. Hossmann KA. Pathophysiology and Therapy of Experimental Stroke. Cell Mol Neurobiol 2006, 26:1055-1081.
3. McColl BW, Rothwell NJ, Allan SM. Systemic Inflammation Alters the Kinetics of Cerebrovascular Tight Junction Disruption after Experimental Stroke in Mice. J Neurosci 2008, 28:9451-9462. 10.1523/JNEUROSCI.2674-08.2008, 18799677.
4. Trendelenburg G. Acute neurodegeneration and the inflammasome: central processor for danger signals and the inflammatory response?. J Cereb Blood Flow Metab 2008, 28:867-881. 10.1038/sj.jcbfm.9600609, 18212795.
5. Ducruet AF, Zacharia BE, Hickman ZL, Grobelny BT, Yeh ML, Sosunov SA, Connolly ES. The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol 2009, 219:398-403. 10.1016/j.expneurol.2009.07.018, 19632224.
6. Pedersen ED, Løberg EM, Vege E, Daha MR, Maehlen J, Mollnes TE. In situ deposition of complement in human acute brain ischaemia. Scand J Immunol 2009, 69:555-562. 10.1111/j.1365-3083.2009.02253.x, 19439017.
7. Komotar RJ, Starke RM, Arias EJ, Garrett MC, Otten ML, Merkow MB, Hassid B, Mocco J, Sughrue ME, Kim GH, Mack WJ, Ducruet AF, Connolly ES. The Complement Cascade: New Avenues in Stroke Therapy. Curr Vasc Pharmacol 2009, 7:287-292. 10.2174/157016109788340677, 19601853.
8. Széplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Karádi I, Entz L, Széplaki Z, Garred P, Prohászka Z, Füst G. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 2009, 204:315-20. 10.1016/j.atherosclerosis.2008.07.044, 18804761.
9. Figueroa E, Gordon LE, Feldhoff PW, Lassiter HA. The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett 2005, 380:48-53. 10.1016/j.neulet.2005.01.027, 15854749.
10. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, Bergamaschini L, De Simoni MG. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2006, 19:10-17.
11. Stahel P, Flierl M, Morgan BP, Persigehl I, Stoll C, Conrad C, Touban B, Smith W, Beauchamp K, Schmidt O, Ertel W, Leinhase I. Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. J Neuroinflammation 2009, 6:2. 10.1186/1742-2094-6-2, 2631471, 19133139.
12. Sugita Y, Masuho Y. CD59: its role in complement regulation and potential for therapeutic use. Immunotechnol 1995, 1:157-168.
13. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990, 71:1-9. 1384213, 1698710.
14. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1999, 264:1-14.
15. Kilgore KS, Flory CM, Miller BF, Evans VM, Warren JS. The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996, 149:953-61. 1865152, 8780399.
16. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009, 104:550-8. 10.1161/CIRCRESAHA.108.191361, 19131645.
17. Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003, 23:955-60.
18. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001, 98:442-449. 10.1182/blood.V98.2.442, 11435315.
19. Trendelenburg M. Complement inhibition by anti-C5 antibodies--from bench to bedside and back again. Swiss Med Wkly 2007, 137:413-7.
20. Turnberg D, Botto M, Lewis M, Zhou W, Sacks SH, Morgan BP, Walport MJ, Cook HT. CD59a Deficiency Exacerbates Ischemia-Reperfusion Injury in Mice. Am J Pathol 2004, 165:825-832. 1618586, 15331407.
21. van Beek J, van Meurs M, 't Hart BA, Brok HPM, Neal JW, Chatagner A, Harris CL, Omidvar N, Morgan BP, Laman JD, Gasque P. Decay-Accelerating Factor (CD55) Is Expressed by Neurons in Response to Chronic but Not Acute Autoimmune Central Nervous System Inflammation Associated with Complement Activation. J Immunol 2005, 174:2353-2365.
22. Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000, 157:905-18. 1885712, 10980130.
23. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced Brain Edema and Infarction Volume in Mice Lacking the Neuronal Isoform of Nitric Oxide Synthase After Transient MCA Occlusion. J Cereb Blood Flow Metab 1996, 16:605-611. 10.1097/00004647-199607000-00010, 8964799.
24. Katchanov J, Waeber C, Gertz K, Gietz A, Winter B, Brück W, Dirnagl U, Veh RW, Endres M. Selective neuronal vulnerability following mild focal brain ischemia in the mouse. Brain Pathol 2003, 13:452-64.
25. Dirnagl U, . Members of the MCAO-SOP Group Standard operating procedures (SOP) in experimental stroke research: SOP for middle cerebral artery occlusion in the mouse. Nature Precedings 2009, Members of the MCAO-SOP Group., http://hdl.handle.net/10101/npre.2009.3492.1
26. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
27. Uitenbroek DG. SISA-Binomial. 1997, , http://www.quantitativeskills.com/sisa/calculations/power.htm
28. Cohen J. Statistical power analysis for the behavioral sciences. 1988, Lawrence Erlbaum Associates, Mahwah, NJ, 2.
29. Gertz K, Priller J, Kronenberg G, Fink KB, Winter B, Schröck H, Ji S, Milosevic M, Harms C, Böhm M, Dirnagl U, Laufs U, Endres M. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res 2006, 99:1132-40. 10.1161/01.RES.0000250175.14861.77, 17038638.
30. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997, 150:2019-31. 1858311, 9176395.
31. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006, 1(147 Suppl):232-40.
32. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM. Complement mediators in ischemia-reperfusion injury. Clinica Chimica Acta 2006, 374:33-45.
33. Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009, 158:1074-1089. 10.1016/j.neuroscience.2008.07.015, 2639633, 18691639.
34. Buerke M, Prüfer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 1998, 286:429-38.
35. Chan RK, Ibrahim SI, Takahashi K, Kwon E, McCormack M, Ezekowitz A, Carroll MC, Moore FD, Austen WG. The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion. J Immunol 2006, 177:8080-5.
36. Leinhase I, Holers VM, Thurman JM, Harhausen D, Schmidt OI, Pietzcker M, Taha ME, Rittirsch D, Huber-Lang M, Smith WR, Ward PA, Stahel PF. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci 2006, 7:55. 10.1186/1471-2202-7-55, 1540436, 16842619.
37. Leinhase I, Rozanski M, Harhausen D, Thurman JM, Schmidt OI, Hossini AM, Taha ME, Rittirsch D, Ward PA, Holers VM, Ertel W, Stahel PF. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation 2007, 4:3. 10.1186/1742-2094-4-13, 1781426, 17207275.
38. Tramontini N, Kuipers P, Huber C, Murphy K, Naylor K, Broady A, Kilgore K. Modulation of Leukocyte Recruitment and IL-8 Expression by the Membrane Attack Complex of Complement (C5b-9) in a Rabbit Model of Antigen-Induced Arthritis. Inflammation 2002, 26:311-319. 10.1023/A:1021420903355, 12546141.
39. Baalasubramanian S, Harris CL, Donev RM, Mizuno M, Omidvar N, Song WC, Morgan BP. CD59a Is the Primary Regulator of Membrane Attack Complex Assembly in the Mouse. J Immunol 2004, 173:3684-3692.
40. Imm MD, Feldhoff PW, Feldhoff RC, Lassiter HA. The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats. Neurosci Lett 2002, 325:175-178. 10.1016/S0304-3940(02)00271-9, 12044649.
41. Pedersen ED, Frøyland E, Kvissel AK, Pharo AM, Skåslhegg B, Rootwelt T, Mollnes TE. Expression of complement regulators and receptors on human NT2-N neurons--Effect of hypoxia and reoxygenation. Mol Immunol 2007, 44:2459-2468. 10.1016/j.molimm.2006.10.022, 17116331.
42. Pedersen ED, Aass HC, Rootwelt T, Fung M, Lambris JD, Mollnes TE. CD59 efficiently protects human NT2-N neurons against complement-mediated damage. Scand J Immunol 2007, 66:345-51. 10.1111/j.1365-3083.2007.01959.x, 17635812.
43. Chen CH, Toung TJ, Hurn PD, Koehler RC, Bhardwaj A. Ischemic neuroprotection with selective kappa-opioid receptor agonist is gender specific. Stroke 2005, 36:1557-61. 10.1161/01.STR.0000169928.76321.3d, 15933260.
44. Nijboer CH, Groenendaal F, Kavelaars A, Hagberg HH, van Bel F, Heijnen C. Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J Cereb Blood Flow Metab 2007, 27:282-92. 10.1038/sj.jcbfm.9600342, 16736041.
45. Palmon SC, Williams MJ, Littleton-Kearney MT, Traystman RJ, Kosk-Kosicka D, Hurn PD. Estrogen increases cGMP in selected brain regions and in cerebral microvessels. J Cereb Blood Flow Metab 1998, 18:1248-52. 10.1097/00004647-199811000-00011, 9809514.
46. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002, 3:433-442.
47. Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997, 31:1-11. 10.1007/BF02815156, 9271001.
48. Asbury ET, Fritts ME, Horton JE, Isaac WL. Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav Brain Res 1098, 97:99-106.
49. Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005, 1049:112-119. 10.1016/j.brainres.2005.05.004, 15932748.
50. Roof RL, Duvdevani R, Heyburn JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol 1996, 138:246-251. 10.1006/exnr.1996.0063, 8620923.
51. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002, 178:59-67. 10.1006/exnr.2002.8020, 12460608.
52. Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999, 24:2134-2138. 10.1097/00007632-199910150-00013, 10543012.
53. Wright DW, Ritchie JC, Mullins RE, Kellermann AL, Denson DD. Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J Clin Pharmacol 2005, 45:640-648. 10.1177/0091270005276201, 15901745.
54. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007, 49:391-402. 402 e391-392, 10.1016/j.annemergmed.2006.07.932, 17011666.
55. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004, 172:3869-75.
56. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009, 68:217-26. 10.1097/NEN.0b013e3181996688, 19225414.
57. Ramaglia V, King RH, Morgan BP, Baas F. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol Immunol 2009, 46:1892-6. 10.1016/j.molimm.2009.01.017, 19246097.
58. Cowell RM, Plane JM, Silverstein FS. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci 2003, 23:9459-68.
59. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, Kindy MS, Tomlinson S. Complement-Dependent P-Selectin Expression and Injury following Ischemic Stroke. J Immunol 2006, 177:7266-7274.
60. del Zoppo GJ. In stroke, complement will get you nowhere. Nat Med 1999, 5:995-6. 10.1038/12431, 10470074.
61. Kolev MV, Tediose T, Sivasankar B, Harris CL, Thome J, Morgan BP, Donev RM. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J 2010, 10:12-9. 10.1038/tpj.2009.52, 19884909.